Allergy, Asthma & Immunology Research. 2025 Nov; 17(6): 8508903. doi: 10.4168/aair.2025.17.6.669
Efficacy of Biologics on Nasal Symptoms in Severe Asthmatics : We Need Additional Biomarkers or Strategies to Assess Phenotypes or Endotypes
Ho Jin Yong , Young-Koo Jee*
expand
-
-
원문보기
-
조회
상세조회 310건
-
-
Abstract
[No Abstract Available]
-
MeSH Term
-
References
more references
1. Sim S, Choi Y, Park HS. Update on inflammatory biomarkers for defining asthma phenotype. Allergy Asthma Immunol Res 2024;16:462-72.
2. Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev 2024;33:230238.
3. Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 2021;9:1133-41.
4. Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021;14:127-34.
5. Bachert C, Maurer M, Palomares O, Busse WW. What is the contribution of IgE to nasal polyposis? J Allergy Clin Immunol 2021;147:1997-2008.
6. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol 2022;149:1286-95.
7. Shim JS, Kim H, Kwon JW, Park SY, Kim S, Kim BK, et al. Impact of biologics on nasal symptoms in severe asthmatics: findings from the PRISM study. Allergy Asthma Immunol Res 2025;17:709-25.
8. Yamani I, Bu Saeed K, Alsulami A, Sait S, Althumali AH. Efficacy of biologic therapies in the management of allergic rhinitis: a systematic review. Cureus 2024;16:e71408.
9. Cavaliere C, Begvarfaj E, Incorvaia C, Sposato B, Brunori M, Ciofalo A, et al. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett 2020;227:81-7.